Acute coronary syndrome - rivaroxaban [ID532]: supporting information

01 – Pre-meeting briefing prepared by NICE

02 – Submission from the technology company – Bayer

03 – NICE request to the company for clarification on their submission

04 – Company’s clarification response

05 – Consultee submission – Pumping Marvellous Foundation

06 – Clinical expert statement – Cotton

07 – Clinical expert statement – Di Mario

08 – Patient expert personal perspective – Hartshorne Evans

09 – Patient expert personal perspective – Knowles Smith

10 – Evidence Review Group report prepared by School of Health Related Research, University of Sheffield

11 – Evidence Review Group report erratum

12 – Company factual accuracy check of Evidence Review Group report


Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 23 October 2014